The Multi-Centre Non-Inferiority Randomized Controlled Trial of STOPping Cardiac MEDications in Patients With Normalized Cancer Therapy Related Cardiac Dysfunction (STOP-MED CTRCD) (NCT06183437),45 due to commence in later 2024, will explore medication withdrawal in a cohort of cancer survivors with prior anthracycline and/or HER2-targeted therapy-related cardiac dysfunction in a larger group (recruitment target 335 participants) with 5 years of planned follow-up. The gene discussed is ERBB2; the disease is cancer.